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Abstract
Background: Ebstein anomaly is a rare congenital heart defect (CHD) that, when severe, 
requires corrective surgery or other catheter-based intervention in the first year of life. Due to its 
rarity, risk factors for Ebstein anomaly remain largely unknown. Using national data, we examined 
18 potential risk factors for Ebstein anomaly.
Methods: Using 1997–2011 data from the National Birth Defects Prevention Study, a 
population-based case-control study, we calculated crude and adjusted odds ratios and 95% 
confidence intervals for paternal age, maternal socio-demographics, reproductive history, and 
modifiable risk factors, and infant characteristics reported by mothers of 135 Ebstein anomaly 
cases and 11,829 controls.
Results: Mothers of Ebstein anomaly cases had 4.1 (95% confidence interval: 1.8, 9.5) times the 
odds of reporting a family history of CHD compared with mothers of controls. Ebstein anomaly 
was associated with maternal second-hand cigarette smoke exposure at home (odds ratio = 2.2 
[95% confidence interval: 1.1,4.4]), but not maternal cigarette smoking (odds ratio = 1.3 [95% 
confidence interval: 0.8, 2.1]). Odds were elevated, but the 95% confidence interval included 1.0, 
for maternal marijuana use (odds ratio = 1.8 [95% confidence interval: 0.9, 3.8]) and paternal age 
≥40 years at delivery (odds ratio = 1.9 [95% confidence interval: 1.0, 3.5]).
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Conclusions: Maternal exposure to second-hand cigarette smoke at home and a family history 
of CHD were associated with elevated odds of Ebstein anomaly. Genetic analyses could clarify the 
potential heritability of Ebstein anomaly.
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Ebstein anomaly is a rare congenital heart defect (CHD) involving abnormal formation and 
position of the tricuspid valve, ranging from minimally symptomatic to critical right heart 
obstruction.1 When severe, Ebstein anomaly is considered a critical CHD requiring 
corrective surgery or other catheter-based intervention in the first year of life to improve 
systemic oxygenation; prognosis for these cases may be poor.2–5 With a prevalence of about 
7 per 100,000 live births, the rarity of Ebstein anomaly has been an obstacle to examining 
potential risk factors.6,7 Several population-based cohorts and case-control studies have 
explored possible risk factors for occurrence of Ebstein anomaly: the Baltimore-Washington 
Infant Study,3,4 Hawaii Birth Defects Program,8 Texas Birth Defects Registry,6 EUROCAT 
multi-registry9 and National Birth Defects Prevention Study (1997–2011).10–12 Results from 
published reports have varied, but one or more have found maternal race, age, pre-pregnancy 
body mass index, lithium use during pregnancy, gastrointestinal medication use during 
pregnancy, anti-hypertensive medication use, marijuana use during pregnancy, proximity of 
residence to the Mexico border, and season of conception to be associated with Ebstein 
anomaly.3,6–8,10–13
While published reports have shed light on some potential risk factors for Ebstein anomaly, 
the small sample size of Ebstein anomaly cases in many studies hinders consistent risk 
estimates. Furthermore, the emphasis of some previous analyses has been on socio-
demographic characteristics, maternal reproductive history (e.g. previous miscarriages), and 
infant-specific characteristics (e.g. gestational age), with less information published on 
potentially modifiable risk factors such as fertility treatments, maternal cigarette smoke 
exposure, maternal alcohol use, prenatal folic acid use, and maternal fever during pregnancy. 
Therefore, using data from the National Birth Defects Prevention Study, the objective of the 
present study was to examine a spectrum of potential risk factors for Ebstein anomaly, 
including modifiable exposures, many of which have not been previously examined.
Materials and methods
Data sources and population
The National Birth Defects Prevention Study is a population-based case-control study that 
examines risk factors for major birth defects. The National Birth Defects Prevention Study is 
a collaborative effort between 10 Centers for Birth Defects Research and Prevention, located 
in Arkansas, California, Iowa, Massachusetts, New Jersey, New York, North Carolina, 
Texas, Utah, and the Centers for Disease Control and Prevention, which also serves as the 
Georgia Center for Birth Defects Research and Prevention. All sites collected data on live 
births with select major birth defects, and most sites additionally collected data on fetal 
deaths after 20 weeks gestation (all except New Jersey and New York prior to 2000) and 
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elective terminations of pregnancy (all except New Jersey and Georgia before 1999 and 
Massachusetts before 2011). Infants with known genetic syndromes and chromosomal 
malformations were ineligible for National Birth Defects Prevention Study. Diagnoses, 
selected demographics, and pregnancy-and birth-related information on cases were 
ascertained from existing population-based active birth defects surveillance systems. 
Controls were live born infants with no major birth defects, who were randomly selected 
from the same source population as cases using either vital records or records from hospitals 
of birth. Case and control infants were born on or after October 1, 1997, and had an 
estimated date of delivery on or before December 31, 2011.
Between 6 weeks and 24 months after the estimated delivery date, mothers of case and 
control infants were invited to participate in a standardised computer-assisted telephone 
interview in either English or Spanish. The interview covered a range of modifiable risk 
factors that may be associated with the risk for birth defects, including infectious, chemical, 
physical, nutritional, and behavioural exposures. From 1997 to 2011, the National Birth 
Defects Prevention Study interview participation rate overall was 67% for cases and 65% for 
controls.14 Each study site and the Centers for Disease Control and Prevention obtained 
Institutional Review Board approval for the study and patients provided informed consent. A 
more detailed description of the National Birth Defects Prevention Study sampling and 
design can be found elsewhere.14,15
Case definition
Abstracted medical information of all cases was reviewed by a clinical geneticist and a 
clinician with expertise in paediatric cardiology to confirm Ebstein anomaly case eligibility.
16
 There were a total of 183 cases of Ebstein anomaly included in the National Birth Defects 
Prevention Study. For this investigation, we restricted our analysis to 135 Ebstein anomaly 
cases who had no major non-cardiac defects and no other cardiac defects aside from 
anomalies that are commonly co-occurring with Ebstein anomaly: pulmonary stenosis, 
ventricular septal defects, and atrial septal defects.
Potential risk factors
We identified 18 maternal, paternal, and infant characteristics to examine as potential risk 
factors for Ebstein anomaly. Maternal factors included age at delivery (<20, 20–34, 35–39, 
≥40 years), race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic, other), pre-
pregnancy body mass index (<25, 25–29, ≥30 kg/m2), and gravidity (0, ≥1); exposures 
reported during the first trimester of pregnancy such as fever (yes, no), folic acid use (yes, 
no), gastrointestinal medication use (yes, no; defined as maternal use of any antacids, anti-
diarrheal agents, anti-emetics, anti-flatulents, and anti-ulcer agents), alcohol use (yes, no), 
marijuana use (yes, no), and cigarette smoke (analysed using three categorisation schemes 
described in more detail later); and any fertility treatment within 2 months prior to 
conception (yes, no; defined as use of any medications, procedures, or surgeries to help 
become pregnant) and maternal use of assisted reproductive technology within 2 months 
prior to conception (yes, no; defined as use of in vitro fertilisation or intra-cytoplasmic 
sperm injection). Paternal factors included age at delivery (<20, 20–34, 35–39, ≥40 years). 
Infant characteristics included 1st degree family history of CHDs (i.e. mother, father, or 
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sibling of case with CHD; yes, no), season of conception (spring: March-May; summer: 
June-August; fall: September-November; winter: December-February), sex (male, female), 
plurality (singleton, multiple), and year of birth (1997–2001, 2002–2006, 2007–2011). 
Maternal lithium exposure during pregnancy was also examined as a potential risk factor, but 
the sample size of exposed cases (n = 1) and controls (n = 8) was insufficient for further 
analysis.
Similar to a previous National Birth Defects Prevention Study analysis,17 maternal cigarette 
smoke exposure was assessed using the following three categorisation schemes: any 
cigarette smoke exposure (maternal smoking regardless of second-hand smoke exposure; 
second-hand smoke exposure at home, work or school; no cigarette smoke exposure); 
second-hand cigarette smoke exposure at home among non-smokers (yes, no); and second-
hand cigarette smoke exposure at work or school among non-smokers (yes, no). For 
maternal exposures reported during pregnancy, mothers were considered exposed if they 
reported the exposure from the month prior to conception through the end of the 1st 
trimester of pregnancy (hereafter referred to as 1st trimester) and unexposed if they did not 
report the exposure from 3 months before the date of conception to the estimated date of 
delivery (hereafter referred to as pregnancy). Mothers exposed outside of the exposure 
window of interest only were excluded. However, in two sensitivity analyses, we included 
mothers exposed outside the original exposure window (i.e. those excluded from the original 
analyses) and categorised them as either exposed (broadening the exposure window to all of 
pregnancy) or unexposed.
Potential confounders
Potential confounders for each of the 18 risk factor analyses were selected based on reported 
associations from previous literature and theoretical associations using directed acyclic 
graphs. Each risk factor model was considered separately, and thus potential con-founders 
varied across the 18 models. All multi-variable models included maternal age at delivery, 
maternal race/ethnicity, maternal pre-pregnancy body mass index, family history of CHDs, 
season of conception, maternal marijuana use, paternal age at delivery, and birth year. In 
addition to the variables listed earlier, anti-hypertensive medication use was included in the 
model examining maternal body mass index, and gastrointestinal medication use was 
included in the model examining maternal fever. Report of anti-hypertensive medication use 
was not assessed as an independent risk factor of interest in this analysis because two recent 
National Birth Defects Prevention Study analyses have already reported an association 
between Ebstein anomaly and anti-hypertensive medication use.10,11
Analysis
Descriptive statistics among Ebstein anomaly cases and controls were examined using chi-
square tests, with a p value of <0.05 considered statistically significant. To assess the 
association between each of the 18 potential risk factors of interest and Ebstein anomaly, we 
used logistic regression to estimate crude odds ratios, adjusted odds ratios, and 
corresponding 95% confidence intervals. All statistical analyses were conducted using SAS 
version 9.4 (SAS Institute, Cary, North Carolina).
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Results
There were 135 Ebstein anomaly cases that met our case definition and 11,829 controls in 
National Birth Defects Prevention Study between 1997 and 2011 (Fig 1). Maternal and 
infant characteristics of Ebstein anomaly cases were similar to those of controls: about 76% 
of mothers were between 20 and 34 years of age at the time of delivery, about 60% were 
non-Hispanic white, and about 50% of infants were male (Table 1). However, more case 
mothers than control mothers reported a 1st degree family history of CHD (5% and 1%, 
respectively, p < 0.01) and exposure to anti-hypertensive medications during pregnancy (5% 
and 2%, respectively, p < 0.01). No other differences between cases and controls were 
statistically significant.
Only family history of CHD and maternal second-hand cigarette smoke exposure were 
significantly associated with Ebstein anomaly (Table 2). Ebstein anomaly case mothers had 
4.1 (95% confidence interval: 1.8, 9.5) times the odds of reporting a 1st degree family 
history of CHD compared with control mothers. After excluding women who smoked 
cigarettes, case mothers had 2.0 (95% confidence interval: 1.2, 3.2) times the odds of 
second-hand smoke exposure compared with control mothers. However, maternal smoking 
during the first trimester, regardless of second-hand smoke exposure, was not associated 
with Ebstein anomaly (adjusted odds ratio = 1.3 [95% confidence interval: 0.8, 2.1]). After 
excluding smokers, case mothers had elevated odds of reporting second-hand smoke 
exposure at home (adjusted odds ratio = 2.2 [95% confidence interval: 1.1, 4.4]) and at work 
(adjusted odds ratio =1.8 [95% confidence interval: 0.9, 3.6]); however, the latter did not 
reach statistical significance. We also observed borderline statistically significant elevated 
odds of Ebstein anomaly for fathers aged 40 years and older (adjusted odds ratio = 1.9 [95% 
confidence interval: 1.0, 3.5]). The odds of case mothers reporting marijuana use was 
elevated, but not statistically significant (adjusted odds ratio =1.8 [95% confidence interval: 
0.9, 3.8]). The results of both sets of sensitivity analyses did not substantially alter results.
Discussion
In this risk factor analysis with the largest sample of Ebstein anomaly cases published thus 
far, we observed higher odds of Ebstein anomaly among cases with family histories of CHD 
and maternal second-hand cigarette smoke exposure at home. We also found elevated but not 
statistically significant odds of Ebstein anomaly among infants born to fathers 40 years of 
age and older, mothers with second-hand cigarette smoke exposure at work, and mothers 
reporting marijuana use. There may be a genetic component with Ebstein anomaly as 
evidenced by the four times higher odds observed among those with a family history of 
CHD in this analysis. Although there does not appear to be any prior study that has analysed 
a family history of CHD and Ebstein anomaly specifically, several studies point to a genetic 
component in the heritability of non-syndromic CHD and right ventricular outflow defects, a 
group in which Ebstein anomaly is often included.18–20 The recurrence rate of CHD overall 
was about 4% in the offspring of 1,483 women reporting a family history of CHD who 
participated in a clinical study in Italy.19 In a Danish national cohort study, the recurrence 
risk ratio of right ventricular outflow defects was 48.6 (95% confidence interval: 27.5, 85.6) 
among infants with 1st degree relatives that also had right ventricular outflow defects.18 
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Familial incidence of any cardiovascular malformation was 11% among 1st degree relatives 
of hypoplastic left heart syndrome cases in a United States-based clinical study.20 However, 
in our study, which excludes infants with known genetic syndromes and chromosomal 
malformations, only 5% of Ebstein anomaly cases reported a 1st degree family history of 
CHD, suggesting that genetics may not explain the large majority of isolated Ebstein 
anomaly cases, though further study is required.
We also found that maternal second-hand cigarette smoke exposure, specifically at home, 
but not maternal cigarette smoking itself was associated with increased odds of Ebstein 
anomaly in the infant. Other National Birth Defects Prevention Study analyses have found 
similar associations between maternal second-hand smoke exposure and congenital limb 
deficiencies, anorectal atresia, neural tube defects, and orofacial clefts.21–24 Maternal 
second-hand cigarette smoke exposure at home may be a proxy for paternal cigarette 
smoking or unmeasured socio-demographic or biological factors associated with both 
second-hand smoke exposure and Ebstein anomaly. A meta-analysis of 125 studies found an 
elevated risk of CHDs associated with maternal passive smoking as well as paternal active 
smoking.25 The increasing body of evidence observing associations between maternal 
second-hand cigarette smoke exposure during pregnancy and birth defects is supported by 
findings that second-hand smoke introduces higher concentrations of some toxic constituents 
than maternal smoking.26
The evidence supporting an association between paternal age and CHDs is varied. We 
observed non-significant but elevated odds of Ebstein anomaly among infants born to fathers 
over 40 years of age. Using data from the Texas Birth Defects Registry, Lupo et al. found no 
association between paternal age and Ebstein anomaly.6 An analysis using national registry 
data in Denmark assessing the association between paternal age and all CHDs combined as 
well as a few specific CHD sub-types other than Ebstein anomaly reported that older 
paternal age was associated with elevated risk of patent ductus arteriosus only.27 A previous 
National Birth Defects Prevention Study analysis using data from 1997 to 2004 reported an 
elevated odds of right ventricular outflow tract obstruction and pulmonary valve stenosis for 
each year increase in paternal age.28
Our analyses could not confirm several associations with Ebstein anomaly reported in 
previously published literature. Correa-Villasenor et al. identified mothers 30 years and older 
at delivery and Lupo et al. identified women older than 39 years at delivery to be more likely 
than younger women to deliver an infant with Ebstein anomaly.3,6 Our results showed no 
association between Ebstein anomaly and maternal age at delivery. In previous literature on 
race and ethnicity, offspring of mothers who were non-Hispanic white tended to be at 
elevated risk for Ebstein anomaly compared with non-white mothers.3,7 Likewise, in our 
analysis, the odds of Ebstein anomaly was lower among non-Hispanic blacks (adjusted odds 
ratio = 0.6 [95% confidence interval: 0.3, 1.2]) compared with non-Hispanic whites; 
however, the confidence interval was wide and included 1.0. Unlike a previous National 
Birth Defects Prevention Study analysis using data from 1997 to 2004,12 we did not observe 
an association between Ebstein anomaly and maternal pre-pregnancy overweight or obesity 
(data not shown). In a previous study, infants conceived in the fall or winter had higher odds 
of Ebstein anomaly than those conceived in the summer6; however, we observed no 
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association between season of conception and Ebstein anomaly. While maternal marijuana 
use was not significantly associated with Ebstein anomaly in this analysis, we observed an 
elevated odds ratio in both crude and adjusted analyses. Correa-Villasenor et al. identified 
maternal marijuana use to be significantly associated with Ebstein anomaly in crude 
analyses; however, they found the odds ratio was elevated but no longer statistically 
significant after adjustment for confounders.3 In the same study, infants with Ebstein 
anomaly were found to be three times more likely to have a mother who used 
gastrointestinal medications during pregnancy, whereas we found no association.3 These 
differences between our findings and others may be the consequence of low exposure 
prevalence in our sample or a small case sample size, despite having the largest sample size 
of any risk factor analysis on Ebstein anomaly thus far. The present study adds to the body 
of evidence on risk factors associated with Ebstein anomaly, which will help identify true 
associations as opposed to spurious findings.
There are several limitations to the present study. All exposures are self-reported by the 
mother and misclassification may occur if the mother cannot remember the timing of her 
exposure or is reluctant to disclose socially undesirable behaviours (e.g. prenatal alcohol 
use). Additionally, maternal smoke exposure is self-reported and smokers may report only 
second-hand smoke exposure rather than their own smoking behaviours because of social 
desirability, leading to misclassification of smoking exposure.29 Differential recall bias may 
occur if mothers of cases were better able to recall details of exposures that they believed to 
be related to the outcome than mothers of controls. We note that 30% of eligible mothers did 
not complete the computer-assisted telephone interview; however, the 70% response rate is 
relatively high for a large case-control study, and the control patients are representative of 
their base populations.30
The multiple testing we performed with 18 potential risk factors increases the likelihood that 
some of our findings may be due to chance. However, selection of exposures was based on 
previously published literature and theoretically plausible etiologies; therefore, multiple 
inference procedures are not advised.31 Previous literature considers maternal lithium 
exposure to be an important risk factor for Ebstein anomaly,13 but we did not have sufficient 
sample size of exposed mothers (only 1 exposed case mother and 8 exposed control 
mothers) to examine lithium in this analysis. We suspect that paternal smoking may be a 
potential risk factor given the association between Ebstein anomaly and second-hand smoke 
exposure at home, but we could not include paternal tobacco smoking in our analysis. Even 
with these limitations, this is the largest population-based analysis of risk factors for Ebstein 
anomaly. Because of both sample size and the variety of questions included in the maternal 
interview, we were able to consider a wide spectrum of potential risk factors and 
associations, including some not previously examined. Additionally, the present study had 
the advantage of a refined case classification involving expert review of medical records.
Conclusion
Compared with mothers of control infants, mothers of Ebstein anomaly cases had higher 
odds of maternal second-hand cigarette smoke exposure at home and a family history of 
CHD; additional research is needed to further investigate these associations. Future studies 
Downing et al. Page 7
Cardiol Young. Author manuscript; available in PMC 2020 June 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
could assess how paternal tobacco exposure and other factors associated with maternal 
second-hand smoke exposure affect the risk for Ebstein anomaly. Additionally, genetic 
analyses could evaluate the potential heritability of isolated Ebstein anomaly.
Acknowledgements.
The authors thank Shannon Pruitt for replicating the results. We thank the families who participated in the National 
Birth Defects Prevention Study, which made this research possible. The authors also thank each site’s clinical 
geneticist, abstractors, study coordinators, and study investigators. This project was supported in part by an 
appointment to the Internship/Research Participation Program at the Centers for Disease Control, administered by 
the Oak Ridge Institute for Science and Education through an interagency agreement between the US Department 
of Energy and EPA.
Financial Support. No honorarium, grant, or other form of payment was given to anyone to produce the 
manuscript.
References
1. Cetta F, Dearani JA, O’Leary PW, Driscoll DJ. Chapter 38: tricuspid valve disorders: atresia, 
dysplasia, and Ebstein anomaly In: Moss & Adams’ Heart Disease in Infants, Children, and 
Adolescents, Including the Fetus and Young Adult. Vol 2, 9th edn Lippincott Williams & Wilkins, 
Philadelphia, PA, 2016.
2. Attenhofer Jost CH, Connolly HM, Edwards WD, Hayes D, Warnes CA, Danielson GK. Ebstein’s 
anomaly-review of a multifaceted congenital cardiac condition. Swiss Med Wkly 2005; 135: 269–
281. [PubMed: 15986264] 
3. Correa-Villasenor A, Ferencz C, Neill CA, Wilson PD, Boughman JA. Ebstein’s malformation of 
the tricuspid valve: genetic and environmental factors. The Baltimore-Washington Infant Study 
Group. Teratology 1994; 50: 137–147. [PubMed: 7801301] 
4. Roberson DA, Silverman NH. Ebstein’s anomaly: echocardiographic and clinical features in the 
fetus and neonate. J Am Coll Cardiol 1989; 14: 1300–1307. [PubMed: 2808987] 
5. Zeng Z, Zhang H, Liu F, Zhang N. Current diagnosis and treatments for critical congenital heart 
defects. Exp Ther Med 2016; 11: 1550–1554. [PubMed: 27168772] 
6. Lupo PJ, Langlois PH, Mitchell LE. Epidemiology of Ebstein anomaly: prevalence and patterns in 
Texas, 1999–2005. Am J Med Genet A 2011; 155a: 1007–1014. [PubMed: 21465650] 
7. Correa-Villasenor A, McCarter R, Downing J, Ferencz C. White-black differences in cardiovascular 
malformations in infancy and socioeconomic factors. The Baltimore-Washington Infant Study 
Group. Am J Epidemiol 1991; 134: 393–402. [PubMed: 1877600] 
8. Forrester MB, Merz RD. Descriptive epidemiology of selected congenital heart defects, Hawaii, 
1986–1999. Paediatr Perinat Epidemiol 2004; 18: 415–424. [PubMed: 15535817] 
9. Knudsen TM, Hansen AV, Garne E, Andersen AM. Increased risk ofsevere congenital heart defects 
in offspring exposed to selective serotonin-reup-take inhibitors in early pregnancy - an 
epidemiological study using validated EUROCAT data. BMC Pregnancy Childbirth 2014; 14: 333. 
[PubMed: 25258023] 
10. Caton AR, Bell EM, Druschel CM, et al. Antihypertensive medication use during pregnancy and 
the risk of cardiovascular malformations. Hypertension 2009; 54: 63–70. [PubMed: 19433779] 
11. Fisher SC, Van Zutphen AR, Werler MM, et al. Maternal antihypertensive medication use and 
congenital heart defects: updated results from the National Birth Defects Prevention Study. 
Hypertension 2017; 69: 798–805. [PubMed: 28373593] 
12. Gilboa SM, Correa A, Botto LD, et al. Association between prepregnancy body mass index and 
congenital heart defects. Am J Obstet Gynecol 2010; 202: 51.e1–e10. [PubMed: 19796755] 
13. Patorno E, Huybrechts KF, Hernandez-Diaz S. Lithium use in pregnancy and the risk of cardiac 
malformations. New Engl J Med 2017; 377: 893–894.
14. Reefhuis J, Gilboa SM, Anderka M, et al. The National Birth Defects Prevention Study: a review 
of the methods. Birth Defects Res A Clin Mol Teratol 2015; 103: 656–669. [PubMed: 26033852] 
Downing et al. Page 8
Cardiol Young. Author manuscript; available in PMC 2020 June 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
15. Yoon PW, Rasmussen SA, Lynberg MC, et al. The National Birth Defects Prevention Study. Public 
Health Rep 2001; 116 Suppl 1: 32–40.
16. Botto LD, Lin AE, Riehle-Colarusso T, Malik S, Correa A. Seeking causes: classifying and 
evaluating congenital heart defects in etiologic studies. Birth Defects Res A Clin Mol Teratol 
2007; 79: 714–727. [PubMed: 17729292] 
17. Caspers KM, Oltean C, Romitti PA, et al. Maternal periconceptional exposure to cigarette smoking 
and alcohol consumption and congenital diaphragmatic hernia. Birth Defects Res A Clin Mol 
Teratol 2010; 88: 1040–1049. [PubMed: 20842650] 
18. Oyen N, Poulsen G, Boyd HA, Wohlfahrt J, Jensen PK, Melbye M. Recurrence of congenital heart 
defects in families. Circulation 2009; 120: 295–301. [PubMed: 19597048] 
19. Fesslova V, Brankovic J, Lalatta F, et al. Recurrence of congenital heart disease in cases with 
familial risk screened prenatally by echocardiography. J Pregnancy 2011; 2011: 368067.
20. Kelle AM, Qureshi MY, Olson TM, Eidem BW, O’Leary PW. Familial incidence of cardiovascular 
malformations in hypoplastic left heart syndrome. Am J Cardiol 2015; 116: 1762–1766. [PubMed: 
26433269] 
21. Miller EA, Manning SE, Rasmussen SA, Reefhuis J, Honein MA. Maternal exposure to tobacco 
smoke, alcohol and caffeine, and risk of anorectal atresia: National Birth Defects Prevention Study 
1997–2003. Paediatr Perinat Epidemiol 2009; 23: 9–17. [PubMed: 19228309] 
22. Suarez L, Ramadhani T, Felkner M, et al. Maternal smoking, passive tobacco smoke, and neural 
tube defects. Birth Defects Res A Clin Mol Teratol 2011;91:29–33. [PubMed: 21254356] 
23. Caspers KM, Romitti PA, Lin S, Olney RS, Holmes LB, Werler MM. Maternal periconceptional 
exposure to cigarette smoking and congenital limb deficiencies. Paediatr Perinat Epidemiol 2013; 
27: 509–520. [PubMed: 24134526] 
24. Hoyt AT, Canfield MA, Romitti PA, et al. Associations between maternal periconceptional 
exposure to secondhand tobacco smoke and major birth defects. Am J Obstet Gynecol 2016; 215: 
613.e1–e11. [PubMed: 27443814] 
25. Zhao L, Chen L, Yang T, et al. Parental smoking and the risk of congenital heart defects in 
offspring: an updated meta-analysis of observational studies. Eur J Prev Cardiol 2019; 0: 1–10.
26. Feldkamp ML, Srisukhumbowornchai S, Romitti PA, Olney RS, Richardson SD, Botto LD. Self-
reported maternal cigarette smoke exposure during the periconceptional period and the risk for 
omphalocoele. Paediatr Perinat Epidemiol 2014; 28: 67–73. [PubMed: 24313669] 
27. Su XJ, Yuan W, Huang GY, Olsen J, Li J. Paternal age and offspring congenital heart defects: a 
national cohort study. PloS One 2015; 10: e0121030.
28. Green RF, Devine O, Crider KS, et al. Association of paternal age and risk for major congenital 
anomalies from the National Birth Defects Prevention Study, 1997 to 2004. Ann Epidemiol 2010; 
20: 241–249. [PubMed: 20056435] 
29. Dietz PM, Homa D, England LJ, et al. Estimates of nondisclosure of cigarette smoking among 
pregnant and nonpregnant women of reproductive age in the United States. Am J Epidemiol 2011; 
173: 355–359. [PubMed: 21178103] 
30. Cogswell ME, Bitsko RH, Anderka M, et al. Control selection and participation in an ongoing, 
population-based, case-control study of birth defects: the National Birth Defects Prevention Study. 
Am J Epidemiol 2009; 170: 975–985. [PubMed: 19736223] 
31. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. 3rd edn Lippincott Williams & 
Wilkins, Philadelphia, 2008.
Downing et al. Page 9
Cardiol Young. Author manuscript; available in PMC 2020 June 04.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 1. 
Exclusion criteria and final sample of Ebstein anomaly cases, National Birth Defects 
Prevention Study, 1997–2011.
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